Shreya Ghanshyambhai Zinzuwadiya, Nimesh P Modi, Keshini S Dhande
{"title":"Management of iron deficiency anemia in pregnancy in India: A review of current practices and challenges","authors":"Shreya Ghanshyambhai Zinzuwadiya, Nimesh P Modi, Keshini S Dhande","doi":"10.18231/j.ijogr.2024.031","DOIUrl":null,"url":null,"abstract":"Iron deficiency anaemia (IDA) is a major global health concern that can lead to difficulties for both the mother and the foetus, especially in pregnant women. The physiological demand of iron during pregnancy increases threefold to support fetoplacental development and maternal adaptation to pregnancy. This study aimed to identify gaps in current IDA management, limitations of conventional oral iron therapy, and the need for effective and well-tolerated treatments.The objective of this study was to understand the gap of current treatment options in IDA management, its limitations, and possible effective strategies for better management.A questionnaire-based opinion survey involving top gynecologists across India was conducted. The survey aimed to gather data on the challenges faced with conventional oral iron therapy, the desire for a change in oral iron salts, and the preference for novel oral iron prescriptions for their patients.Data obtained from the survey showed that 82% of gynecologists and obstetricians noticed challenges with conventional oral iron therapy. 86% wanted to change the oral iron salts, and 70% would like to prescribe novel oral iron for their patients. Ferric maltol, a novel form of chelated oral iron, was introduced as a potential solution for IDA management. It has been studied in various clinical indications, such as IDA associated with inflammatory bowel disease, chronic kidney disease, and pulmonary hypertension, showing significant improvements in hemoglobin and iron indices with good tolerability throughout treatment duration.The study results demonstrate that ferric maltol is a suitable and convenient treatment option for individuals seeking long-term, convenient, and well-tolerated management of IDA.","PeriodicalId":13288,"journal":{"name":"Indian Journal of Obstetrics and Gynecology Research","volume":"83 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Obstetrics and Gynecology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijogr.2024.031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Iron deficiency anaemia (IDA) is a major global health concern that can lead to difficulties for both the mother and the foetus, especially in pregnant women. The physiological demand of iron during pregnancy increases threefold to support fetoplacental development and maternal adaptation to pregnancy. This study aimed to identify gaps in current IDA management, limitations of conventional oral iron therapy, and the need for effective and well-tolerated treatments.The objective of this study was to understand the gap of current treatment options in IDA management, its limitations, and possible effective strategies for better management.A questionnaire-based opinion survey involving top gynecologists across India was conducted. The survey aimed to gather data on the challenges faced with conventional oral iron therapy, the desire for a change in oral iron salts, and the preference for novel oral iron prescriptions for their patients.Data obtained from the survey showed that 82% of gynecologists and obstetricians noticed challenges with conventional oral iron therapy. 86% wanted to change the oral iron salts, and 70% would like to prescribe novel oral iron for their patients. Ferric maltol, a novel form of chelated oral iron, was introduced as a potential solution for IDA management. It has been studied in various clinical indications, such as IDA associated with inflammatory bowel disease, chronic kidney disease, and pulmonary hypertension, showing significant improvements in hemoglobin and iron indices with good tolerability throughout treatment duration.The study results demonstrate that ferric maltol is a suitable and convenient treatment option for individuals seeking long-term, convenient, and well-tolerated management of IDA.
缺铁性贫血(IDA)是全球关注的主要健康问题,会给母亲和胎儿,尤其是孕妇带来困难。孕期对铁的生理需求增加了三倍,以支持胎盘发育和母体对妊娠的适应。本研究旨在找出当前 IDA 管理中的差距、传统口服铁剂疗法的局限性,以及对有效且耐受性良好的治疗方法的需求。本研究的目的是了解当前 IDA 管理中治疗方案的差距、局限性,以及更好管理的可能有效策略。调查旨在收集有关传统口服铁剂疗法所面临的挑战、改变口服铁盐的愿望以及患者对新型口服铁剂处方的偏好等方面的数据。调查数据显示,82% 的妇产科医生注意到传统口服铁剂疗法所面临的挑战。86%的人希望更换口服铁盐,70%的人希望为病人开具新型口服铁剂处方。麦芽酚铁是一种新型的螯合口服铁剂,是治疗 IDA 的潜在解决方案。研究结果表明,麦芽酚铁是一种合适、方便的治疗选择,适合寻求长期、方便、耐受性良好的 IDA 治疗的患者。